Equities research analysts at StockNews.com initiated coverage on shares of Ampio Pharmaceuticals (NYSE:AMPE – Get Free Report) in a note issued to investors on Tuesday. The firm set a “sell” rating on the stock.
Ampio Pharmaceuticals Stock Performance
Shares of NYSE AMPE opened at $0.24 on Tuesday. The stock has a market cap of $272,973.18, a price-to-earnings ratio of -0.02 and a beta of 2.14. Ampio Pharmaceuticals has a 52 week low of $0.14 and a 52 week high of $8.30. The company’s 50-day moving average price is $0.93 and its 200 day moving average price is $1.72.
Ampio Pharmaceuticals (NYSE:AMPE – Get Free Report) last issued its quarterly earnings data on Wednesday, March 27th. The company reported ($2.48) EPS for the quarter.
About Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc, a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.
Featured Stories
- Five stocks we like better than Ampio Pharmaceuticals
- What is the S&P/TSX Index?
- Lucid’s Stock Price is Still in Reverse: New Lows Are Coming
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Generac Powers Ahead on the Electrification Mega-Trend
- 3 Stocks to Consider Buying in October
- PulteGroup Wins and Wins More on Interest Rate Cuts
Receive News & Ratings for Ampio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
